← Human Trials & Peer-Reviewed Studies
Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus.
Plain-language guide to PMID 15203886 (2004): controlled clinical trial of NAD+ in 2 patients.
Key Facts
- PMID
- 15203886
- Journal
- Experimental diabesity research
- Year
- 2004
- Study type
- Controlled Clinical Trial
- Authors
- Osar Z et al. (5 authors)
- DOI
- 10.1080/15438600490424244
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of NAD+, published as a controlled clinical trial.
In order to test the hypothesis, this placebo-controlled and open study was designed to evaluate neutrophil functions in infection-free poorly controlled type 2 diabetic patients as compared to healthy subjects and assess the effects of nicotinamide on neutrophil phagocytosis as well as oxidative burst activity.
Why It Was Studied
Neutrophil functions are impaired in patients with diabetes mellitus.
Defects in neutrophil oxidative burst capacity are of multifactorial origin in diabetes mellitus and correlate with glucose levels.
Who Took Part
The abstract describes 2 patients taking part.
The age groups tagged for this paper are middle-aged adults, both men and women.
Thirty patients with type 2 diabetes mellitus were enrolled in the study.
Phagocytic activity and respiratory burst indexes were measured by flow cytometric analyses as previously described by Rothe and Valet (Methods Enzyml., 233, 539-548, 1994) and compared in diabetic subjects and healthy controls.
How the Study Was Run
The design is described as placebo-controlled.
The comparison arm used a placebo, so changes seen with NAD+ could be set against what happens without it.
What Was Measured
Defects in neutrophil oxidative burst capacity are of multifactorial origin in diabetes mellitus and correlate with glucose levels.
PubMed files the paper under topics including Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Neutrophils, Niacinamide and Phagocytosis.
What This Means in Plain Language
The paper is a placebo-controlled study of NAD+ in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2004 (Experimental diabesity research), a journal based in United States.
More context: the NAD+ compound page, all human trials.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.